Sartorius AG
Makes filters, bioreactors, and lab gear that biologics manufacturers can't easily swap out.
On the record
Checkpoint: Q3/FY2026 results, watch whether advanced-therapy customer order delays spread beyond the two already flagged
The call
Sartorius sits inside a small group of suppliers that all benefit from the same lock-in, with the nearest watch point being whether isolated order delays turn into a pattern.
Sartorius sells machines and filters to drug and cell-therapy makers. Once a customer validates their equipment with the FDA or European regulators, switching to a competitor like Danaher or Thermo Fisher means re-doing all that paperwork and testing, which takes years and costs millions. That lock-in is real and has worked for 156 years. The one thing to watch is whether cell and gene therapy customers start delaying orders again after two already pushed purchases into 2027. If more customers do that, it could signal that the whole advanced-therapy boom is slowing down, which would hurt Sartorius's sales.
Why
01
AI pressure: None apparent. Sartorius sells AI-based process software like Biobrain to its own customers; no AI product threatens the physical hardware it makes. Could AI do the core job? Unlikely.
02
Bigger players: Danaher (Cytiva, Pall), Thermo Fisher, Merck KGaA (MilliporeSigma). All three sell competing single-use bioprocessing gear today, but each faces the same regulatory switching costs Sartorius does. Could a giant copy it? No, they are blocked.
03
What protects it. Drug makers must requalify any filter or bioreactor change with FDA/EMA, so validated Sartorius parts stay locked into approved manufacturing lines for decades.
What would change this call
Q3/FY2026 results show a third or fourth cell/gene-therapy customer delaying orders to 2027. Would indicate sector-wide advanced-therapy demand softness rather than an isolated issue.
Sartorius revises FY2026 guidance (5-9% cc growth, ~30% EBITDA margin) at Q3 or FY2026 reporting. Would show underlying demand or margin trends deteriorating beyond current isolated delays.
Elliott/Bio-Rad process results in sale or spin-off of Bio-Rad's Sartorius stake within 6-12 months. Would show a shift in Sartorius shareholder base and stock technicals, not business fundamentals.
Sartorius revises FY2026 guidance (5-9% cc growth, ~30% EBITDA margin) at Q3 or FY2026 reporting. Would show underlying demand or margin trends deteriorating beyond current isolated delays.
Elliott/Bio-Rad process results in sale or spin-off of Bio-Rad's Sartorius stake within 6-12 months. Would show a shift in Sartorius shareholder base and stock technicals, not business fundamentals.
Key numbers
- FY2025 revenue: 3,538 million euros, up 7.6% at constant currency
- 81% of revenue comes from Bioprocess Solutions, mostly recurring consumables
- H1 2026 EBITDA margin: 30.3%, net profit up to 122 million euros
Named risks
- Two advanced-therapy customers delayed orders to 2027; a third emerging would signal sector-wide demand softness.
- Elliott activist pressure on Bio-Rad's Sartorius stake could alter Sartorius's shareholder base if a sale or spin-off occurs.
- Equipment segment cyclicality and post-pandemic destocking still tempering growth despite consumables recovery.
- Dual-class structure with 50.1% family trust control limits minority shareholder influence.
- Pending EU PFAS regulatory decisions could require further filtration product reformulation.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Danaher (Cytiva/Pall) | contesting | Peer-scale oligopolist with equivalent FDA/EMA lock-in; Cytiva holds large chromatography resin share per industry commentary, 2026-06-18 |
| Thermo Fisher Scientific | contesting | Peer-scale competitor in bioprocessing and lab instruments, cited as leading player alongside Sartorius |
| Merck KGaA (MilliporeSigma) | contesting | Cited as leading player in single-use bioprocessing market alongside Danaher |
| Repligen Corporation | contesting | Named direct competitor in bioprocessing/single-use systems and filtration |
| Bio-Rad Laboratories | contesting | Both shareholder (~$5B stake as of 2026-05-18) and peer in life-science tools |
Questions people ask
- Is Sartorius AG profitable in 2026?
- Yes. In H1 2026, Sartorius reported net profit of about €122 million, up from €81 million a year earlier, on adjusted EBITDA of €548 million (30.3% margin) and revenue of €1.81 billion, per results published 2026-07-23.
- Who owns Sartorius AG?
- The Sartorius Trust, a family trust of the founder's descendants, holds 50.1% of ordinary shares, giving the family control. Bio-Rad Laboratories is a large minority investor, with its Sartorius stake valued at roughly $5 billion as of 2026-05-18 reporting.
- Could AI replace Sartorius AG's products?
- No. Sartorius sells physical, GMP-regulated bioprocessing hardware and single-use consumables that require FDA/EMA re-qualification to switch, a process taking 6-18 months. Sartorius sells AI-adjacent tools like Biobrain Operate to customers, it is not disrupted by AI.
- Who is Sartorius AG's biggest competitor?
- Sartorius competes with peer-scale oligopolists Danaher (via Cytiva and Pall), Thermo Fisher Scientific, Merck KGaA (MilliporeSigma), and Repligen in bioprocessing and filtration, none of which holds a decisive speed advantage given shared regulatory lock-in dynamics as of 2026.
- Is Sartorius AG cutting jobs or laying off staff in 2025-2026?
- No layoffs are reported. Sartorius employed 13,878 people as of September 30, 2025, up 350 from year-end 2024, driven by production hiring, with year-end 2025 headcount rising further to roughly 14,000-14,042 employees.
- What is Sartorius AG's 2026 revenue guidance?
- Sartorius guided FY2026 constant-currency revenue growth of 5-9% and an underlying EBITDA margin slightly above 30%, issued with FY2025 preliminary results on 2026-02-03 and reaffirmed at Q2 2026 reporting on 2026-07-23.
Timeline
- 2026-07-23H1 2026 results: revenue €1.81B, +7.7% organic, net profit €122M vs €81M YoY
- 2026-05-18Elliott Investment Management discloses stakes in Bio-Rad and Sartorius
- 2026-03-26AGM covers 2025 results, dividend plan, and 2026 outlook
- 2026-02-16Sartorius releases Annual Report for 2025
- 2026-02-03FY2025 preliminary results: revenue €3,538M, EBITDA margin 29.7%
- 2025-10-169M 2025 results reported; headcount at 13,878, up 350 YoY
- 2025-07-01Michael Grosse becomes CEO, succeeding Joachim Kreuzburg
- 2025-04-09Sartorius and Tulip Interfaces partner on Biobrain Operate MES
- 2025-04-04Sartorius agrees to acquire MatTek Corp from BICO Group
- 2025-02-14PFAS-free Sartopore Evo filtration membrane application note published
Revision history
24 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Sartorius achieves considerable profitable growth in 2025 (2026-02-03)
- Consumables driver: Sartorius keeps picking up speed (2026-07-23)
- SAG Factsheet FY2025
- Sartorius Q2 Earnings Call Highlights (2026-07-23)
- CORRESP
- Elliott Investment takes stake in Sartorius, Bio-Rad Laboratories (2026-05-18)
- 2025 Sales Hit €3.5B, New CEO, Dividend Plan and 2026 Outlook (2026-03-26)
- Sartorius sharpens guidance after significantly profitable sales revenue growth in the first nine months (2025-10-16)
- Sartorius to acquire MatTek (2025-04-04)
- Sartorius Stedim Biotech and Tulip partner to drive end-to-end biomanufacturing visibility and optimization (2025-04-09)
- Sartopore Evo, Embracing a PFAS-Free Future (2025-02-14)
- AGM Sartorius AG